DrugPatentWatch Database Preview
Investigational Drug Information for Entinostat
Email this page to a colleague
What is the drug development status for Entinostat?
Entinostat is an investigational drug.
There have been 69 clinical trials for Entinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 29th 2014.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Syndax Pharmaceuticals, and Merck Sharp & Dohme Corp.
There are six hundred and eighty-four US patents protecting this investigational drug and six international patents.
Summary for Entinostat
| US Patents | 684 |
| International Patents | 6,136 |
| US Patent Applications | 2,401 |
| WIPO Patent Applications | 1,531 |
| Japanese Patent Applications | 777 |
| Clinical Trial Progress | Phase 2 (2014-03-29) |
| Vendors | 98 |
Recent Clinical Trials for Entinostat
| Title | Sponsor | Phase |
|---|---|---|
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Entinostat
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
US Patents for Entinostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Entinostat | ⤷ Try it Free | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Try it Free |
| Entinostat | ⤷ Try it Free | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Try it Free |
| Entinostat | ⤷ Try it Free | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Try it Free |
| Entinostat | ⤷ Try it Free | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try it Free |
| Entinostat | ⤷ Try it Free | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try it Free |
| Entinostat | ⤷ Try it Free | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Try it Free |
| Entinostat | ⤷ Try it Free | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III | Frequency Therapeutics, Inc. (Woburn, MA) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Entinostat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Entinostat | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Try it Free |
| Entinostat | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Try it Free |
| Entinostat | Spain | ES2823756 | 2034-04-16 | ⤷ Try it Free |
| Entinostat | Japan | JP2017514806 | 2034-04-16 | ⤷ Try it Free |
| Entinostat | Japan | JP2019070012 | 2034-04-16 | ⤷ Try it Free |
| Entinostat | Japan | JP2021059548 | 2034-04-16 | ⤷ Try it Free |
| Entinostat | Japan | JP6838085 | 2034-04-16 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
